Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

Seven presentations on electroCore’s treatment for cluster headache and migraine will feature at American Headache Society science meeting.

June 8, 2016 at 12:00 AM EDT
Recent clinical and preclinical results using electroCore’s non-invasive vagus nerve stimulation (nVNS, gammaCore®) therapy in the treatment and prevention of primary headache are the subject of seven presentations at the American Headache Society (AHS) Science Meeting being held at San Diego next week (June 9th to 12th). 

The seven accepted abstracts are based on work conducted at universities across the US and Europe. They report on how nVNS is effective in many patients in preventing cluster headache attacks, decreasing the number of menstrual migraines and provide additional preclinical and clinical data that further demonstrates how nVNS may work. 

The platform presentations are: 

“Does Non-invasive Vagus Nerve Stimulation with gammaCore® Acutely Normalize Habituation of Visual Evoked Potentials in Migraine Patients?” 

Institutions involved: Headache Research Unit, Department of Neurology, University of Liège, Belgium 

10 June 11:45am – 1:15pm 



“Non-invasive Vagus Nerve Stimulation for Chronic Cluster Headache: Effects on Attack Frequency Over Time and Response Rates” 

Institutions involved: The Migraine and Headache Clinic, Konigstein, Germany on behalf of the PREVA Study Group. 

11 June 10:30am – 12:30pm 



“Vagus Nerve Stimulation Inhibits Acute Intracranial Dural-Nociceptive Activation of Central Trigeminovascular Neurons” 

Institutions involved: The Department of Maxillofacial pathology, and Radiology and Medicine, NY University College of Dentistry 

11 June 2:00pm – 3:30pm 



“Vagal Nerve Stimulation Suppresses Activation of Trigeminal Nociceptive Neurons in an Animal Model of Migraine Involving Trigeminal Sensitization” 

Institutions involved: The Centre for Biomedical and Life Sciences, Missouri State University 

11 June 2pm – 3:30pm 



The posters due to be presented are: 

“Open-label Pilot Study of Non-invasive Vagus Nerve Stimulation for the Prevention of Menstrual Migraine and Menstrually Related Migraine” 

Institutions involved: Headache Center, Carlo Besta Neurological Institute and Foundation, Milan, Italy; Headache and Pain Unit, Istituti di Ricovero e Cura Carattere Scientifico, San Raffaele Pisana, Rome, Italy; and the Carolina Headache Institute, USA 

11 June 8:00am – 4:30pm 



“Neuronal Targets of Non-Invasive Vagus Nerve Stimulation: A Computational Modeling Study” 

Institutions involved: The Department of Biomedical Engineering, City College of New York; and the University of California Centre for Pain Medicine 

11 June 8:00am – 4:30pm 



Non-invasive Vagus Nerve Stimulation with gammaCore® in Healthy Subjects: Is There Electrophysiological Evidence for Activation of Vagal Afferents? 

Institutions involved: Headache Research Unit, Department of Neurology, University of Liège, Belgium 

11 June 8:00am – 4:30pm 



www.electrocore.com 



Notes to editors 

About electroCore 
electroCore LLC, the New Jersey based bioelectric pharma company, is focused on developing non-invasive vagus nerve stimulation therapies (the gammaCore device) for the treatment of multiple conditions in neurology, psychiatry, gastroenterology, and respiratory fields. The company’s initial target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep, and pain disorders that drive disproportionately large direct and indirect costs within the healthcare system and society.